|
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study |
|
|
|
Titel: |
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study |
Auteur: |
GomezMancilla, Baltazar Meriggioli, Matthew N. Genge, Angela Roubenoff, Ronenn EspiƩ, Pascal Dupuy, Cyrielle Hartmann, Nicole Pezous, Nicole Kinhikar, Arvind Tichy, Mia Dionne, Annie Vissing, John Andersen, Henning Schoser, Benedikt Meisel, Andreas Jordan, Berit Devlikamova, Farida Poverennova, Irina Stuchevskaya, Fatima Lin, Thy-Sheng Rush, James S. Gergely, Peter |
Verschenen in: |
Journal of clinical neuroscience |
Paginering: |
Jaargang 119 () nr. C pagina's 76-84 |
Jaar: |
2024 |
Inhoud: |
|
Uitgever: |
Elsevier Ltd |
Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|